Φ
biolytics

pharma

The sexually transmitted pathogen - Neisseria gonorrhoeae - is the cause of gonorrhea - affecting more than 100 million every year.


N. gonorrhoeae is able to infect the eye, pharynx, anus/rectum, urogenital tract, and may be disseminated throughout the body in more complex cases, where the pathogen may induce serious illness, such as chronic pelvic inflammatory disease, ectopic pregnancy and infertility.


It is generally recognised as a bacterial infection affecting primarily young people, but due to more recent change in sexual behaviour and praxis, it has been affecting an increasing number of adults and older humans.


Previously the treatment has primarily been a simple prescription of antibiotic therapy.


However - N. gonorrhoeae has developed resistance to all the antibiotic drugs used for treatment and has become much more difficult to treat. Today, the emergence of extensive drug resistant and even untreatable gonorrhea has been reported from different areas of the world.


Antibiotic resistant N. gonorrhoeae is a growing public health concern and has dramatic implications on the recommended praxis of treatment.


This project concerns development of a novel and efficient therapy for use in treatment of antibiotic resistant N. gonorrhoeae.


Further information and how you can support this project please contact Biolytics Pharma.